Merck Races to Launch Subcutaneous Keytruda Amid Looming Patent Expiry for IV...

Published on 14 Jan 2025 on GuruFocus.com · via Yahoo Finance

In extending patent protection for its primary cancer medication, Keytruda, Merck (NYSE:MRK) intends...

Read the rest of the article

Start tracking your investments with Statfolio

Merck CEO Rob Davis told CNBC's Jim Cramer that there's more to the pharmaceutical giant than its...

CNBC 14 Jan 2025

We recently published an article titled Jim Cramer Discussed These 21 Stocks As Bond Yields Soare...

Insider Monkey · via Yahoo Finance 14 Jan 2025

Merck & Co.’s Keytruda is the world’s best-selling drug and has been a cancer juggernaut for more...

Pharma Voice · via Yahoo Finance 14 Jan 2025

FEATURE Merck is speeding up plans to launch a new version of its top-selling cancer drug Keytrud...

Barrons.com 14 Jan 2025

In extending patent protection for its primary cancer medication, Keytruda, Merck (NYSE:MRK) inte...

GuruFocus.com · via Yahoo Finance 14 Jan 2025

Merck (MRK) closed the latest trading day at $100.98, indicating a +1.74% change from the previou...

Zacks · via Yahoo Finance 13 Jan 2025

We recently compiled a list of the 12 Most Reliable Dividend Stocks To Buy According to Hedge Fun...

Insider Monkey · via Yahoo Finance 13 Jan 2025

Merck & Co.’s Covid-19 antivirals are getting a new lease of life in post-pandemic China, as cat...

Bloomberg 3 Jan 2025

Here are some of the pharma companies that joined Carter in his efforts to leverage the powerful...

Pharma Voice · via Yahoo Finance 3 Jan 2025

Last Friday, the Medicines and Healthcare Products Regulatory Agency approved Merck & Co Inc’s...

Benzinga · via Yahoo Finance 2 Jan 2025